Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | RET fusion |
| Therapy | Zeteletinib |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| RET fusion | lung non-small cell carcinoma | sensitive | Zeteletinib | Phase I | Actionable | In a Phase I trial, Zeteletinib (DS-5010) treatment led to an objective response rate (ORR) of 28% (28/101), disease control rate (DCR) of 58% (59/101), median progression-free survival (mPFS) of 7.16 mo, and median duration of response (mDOR) of 11.10 mo in patients with RET-altered advanced solid tumors, with an ORR of 28% (17/61), DCR of 59% (36/61), mPFS of 6.18 mo, and mDOR of 10.17 mo in patients with non-small cell lung cancer harboring a RET fusion (PMID: 40992271; NCT03780517). | 40992271 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (40992271) | BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study. | Full reference... |